ArticleJournal of the American Chemical Society2026
Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We describe a semisynthetic strategy that unites the versatility of chemical peptide synthesis with the high affinity and specificity of antibody fragments to create conjugates with remarkably potent anti-HIV activity. Using site-selective enzymatic ligation and click chemistry, we assembled nanobody-fusion inhibitor peptide (Nb-FI) conjugates that link synthetic HIV-1 fusion inhibitor peptides to nanobodies targeting host receptors. This modular approach enables variation of Nb-FI linkage geometry, including C-to-C terminal topologies inaccessible by genetic fusion. Selected semisynthetic conjugates exhibit antiviral potencies up to 10,000-fold better than comparator peptides and broad-spectrum activity across diverse HIV strains. Lead semisynthetic conjugates also outperform analogous genetic fusions. These findings underscore the power of combining chemical synthesis, protein engineering, and antibody delivery to leverage proximity effects in blocking viral infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.